COVID may increase blood clot risk in women who are pregnant or taking oestrogen

Organisation: Position: Deadline Date: Location:

COVID-19 may increase the risk of blot clots in women who are pregnant or taking oestrogen with birth control or hormone replacement therapy, according to a new manuscript.

One of the many complications of COVID-19 is the formation of blood clots in previously healthy people. Oestrogen increases the chance of blood clots during pregnancy and in women taking birth control pills or hormone replacement therapy. If infected with COVID-19, these women’s risk of blood clotting could be even higher, and they may need to undergo anticoagulation therapy or to discontinue their oestrogen medicines.

“During this pandemic, we need additional research to determine if women who become infected with the coronavirus during pregnancy should receive anticoagulation therapy or if women taking birth control pills or hormone replacement therapy should discontinue them,” said the study’s corresponding author, Dr Daniel I Spratt, of Maine Medical Centre in Portland, Maine, and Tufts University School of Medicine in Boston. “Research that helps us understand how the coronavirus causes blood clots may also provide us with new knowledge regarding how blood clots form in other settings and how to prevent them.”

Researching and understanding the cause of blood clotting in COVID-19, including the intersecting effects of oestrogen therapy or pregnancy, has several hurdles and will require innovative animal and tissue models.

Conversations between clinicians and basic researchers and between endocrinologists and haematologists are necessary to explore potential interactions between SARS-CoV-2 – the virus that causes COVID-19 – and pregnancy or oestrogen therapy that could guide clinical management.

The manuscript’s co-author is Dr Rachel J Buchsbaum, of Tufts Medical Centre and Tufts University School of Medicine.

 

Endocrine Society material Endocrinology manuscript (pdf)

Receive Medical Brief's free weekly e-newsletter



Related Posts

Thank you for subscribing to MedicalBrief


MedicalBrief is Africa’s premier medical news and research weekly newsletter. MedicalBrief is published every Thursday and delivered free of charge by email to over 33 000 health professionals.

Please consider completing the form below. The information you supply is optional and will only be used to compile a demographic profile of our subscribers. Your personal details will never be shared with a third party.


Thank you for taking the time to complete the form.